Wire · operational-macro
INO Jumps As Inovio Wins Upgrade Ahead Of FDA Decision
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 August 2026 · Fusion42 review
Inovio Pharmaceuticals stock surged nearly 20% following an upgrade by Jefferies, optimistic informal FDA feedback on its INO-3107 candidate for recurrent respiratory papillomatosis, and progress toward potential accelerated approval with an FDA decision expected by October 30, 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech's regulatory risk just narrowed sharply with FDA feedback favouring accelerated approval. Prepare for a surge in investor attention and reposition your capital around clinical milestones hitting before the October 30 decision.
◆ Coverage
1 source · 16 Aug 2026
◆ Related on Wire
◆ Topics